Moreover, Jie et al. (2017) reported that simultaneous blockade of TIM-3 and PD-1 during cetuximab treatment may improve the survival benefit of HNSCC patients. This evidence concerns the gene HAVCR2 and head and neck squamous cell carcinoma.